Classer les publications sur l'année
-
Biométrie et Analyses de bases de données/SNDS
Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study.
LOUBET P, FERNANDES J, DE POUVOURVILLE G, SOSNOWIEZ K, ELONG A, GUILMET C, OMICHESSAN H, BUREAU I, FAGNANI F, EMERY C, NOUR ABOU CHAKRA C.
Journal of Clinical Virology ; 2024; 171
-
Pharmaco-Epidémiologie
Asthma burden according to treatment steps in the French population-based cohort CONSTANCES.
ROCHE N, NADIF R, FABRY-VENDRAND C, PILLOT L, THABUT G, TEISSIER C, BOUEE S, GOLDBERG M, ZINS M.
Respir Med ; 2023;206:107057
-
Biométrie et Analyses de bases de données/SNDS
Nonâtuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study
VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.
BMC Infectious Diseases ; 2021;21(1):1165
-
Pharmaco-Epidémiologie
Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme
TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.
Eur Respir J ; 2020;55(6)
-
Biométrie et Analyses de bases de données/SNDS
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database
BOURDIN A, FABRY-VENDRAND C, OSTINELLI J, AIT-YAHIA M, DARNAL E, BOUEE S, LAURENDEAU C, BUREAU I, GOURMELEN J, CHOUAID C.
J Allergy Clin Immunol Pract ; 2019;7(5):1477-1487
-
Ăconomie de la santĂ©
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MĂLKEN M.
Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456
-
Biométrie et Analyses de bases de données/SNDS
An attempt at modeling COPD epidemiological trends in France
BURGEL PR, LAURENDEAU C, RAHERISON C, FUHRMAN C, ROCHE N.
Respir Res ; 2018;19(1):130
-
Pharmaco-Epidémiologie
Etude de validation de l’Ă©chelle BDI/TDI dans la bronchopneumopathie chronique obstructive
LAURENDEAU C, PRIBIL C, PEREZ T, ROCHE N, M-C SIMEONI, DETOURNAY B
Rev Mal Respir ; 26:735-743
-
Pharmaco-Epidémiologie
Prévalence de la bronchopneumopathie chronique obstructive (BPCO) : estimation pour la France
BENARD E, DETOURNAY B, NEUKIRCH F, PRIBIL C, EL HASNAOUI A
La Lettre du Pneumologue ; 8(4):158-163
-
Pharmaco-Epidémiologie
The SCOPE Study : Healthcare consumption related to patients with Chronic Obstructive Pulmonary Disease in France
DETOURNAY B, PRIBIL C, FOURNIER M, HOUSSET B, HUCHON G, HUAS D, GODARD P, VOINET C, CHANAL I, JOURDANNE C, DURAND-ZALESKI I, the SCOPE Group
Value Health ; 7(2):168-174
-
Ăconomie de la santĂ©
Costs associated with community acquired pneumonia in France
GRECE SABA, LUIZ FLAVIO ANDRADE, JACQUES GAILLAT, PIERRE BONNIN, CHRISTIAN CHIDIAC, HAJNAL-GABRIELA ILLES, HENRI LAURICHESSE, JONATHAN MESSIKA, JEAN-DAMIEN RICARD, BRUNO DETOURNAY, PATRICK PETITPRETZ, GERARD DE POUVOURVILLE
Eur J Health Econom ; 2018;19(4):533-544
-
Ăconomie de la santĂ©
Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011
LAURENDEAU C, CHOUAID C, ROCHE N, TERRIOUX P, GOURMELEN J , DETOURNAY B
Rev Mal Respir ; 2015;32:682-91
-
Ăconomie de la santĂ©
Le coĂ»t de l’asthme en France et les implications Ă©conomiques de son niveau de contĂŽle
GADENNE S, PRIBIL C, CHOUAID C, VERGNENEGRE A, DETOURNAY B
Rev Mal Respir ; 2011;28(4):419-426
-
Ăconomie de la santĂ©
The association between asthma control, health care costs, and quality of life in France and Spain
DOZ M, CHOUAID C, COM-RUELLE L, CALVO E, BROSA M, ROBERT J, DECUYPERE L, PRIBIL C, HUERTA A, DETOURNAY B
BMC Pulm Med ; 2013;22:13-15
  Â